Lawrence Mae FongPleasanton, CA

2001003, Nov 1, 2001

Feb 22, 2001

09/791992

Lawrence Fong - Menlo Park CA, US
Miriam Merad - Palo Alto CA, US
Edgar Engleman - Atherton CA, US

A61K039/12
A61K039/02
A61K039/00

424/204100, 424/277100, 424/234100

The immunogenicity of an antigen is enhanced by increasing the specific antigen presenting function of dendritic cells (DC) in a mammalian host. The host is treated with a DC mobilization agent to increase the number of circulating DC precursors. The host is then given a local, injection of antigen in combination with a DC activating agent. The activation step promotes recruitment and maturation of the DC, along with antigen-specific activation and migration from the tissues to lymphoid organs. These DC then effectively interact with, and present processed antigen to, T cells that are then able to respond to the antigen. In one aspect of the invention, the antigen is a tumor antigen, and is used to enhance the host immune response to tumor cells present in the body.

2011025, Oct 13, 2011

Oct 28, 2009

13/124922

Lawrence H. Fong - Palo Alto CA, US
Serena Kwek Macphee - Oakland CA, US

A61K 39/00
C12N 9/24
C12N 9/00
C07K 14/435
C07K 7/06
A61P 35/00
C12N 9/90
C40B 30/04
C07K 16/40
C07K 16/18
A61P 37/04
C12N 9/12
C07K 7/08

4241841, 435194, 435200, 435183, 530350, 530329, 530328, 530327, 530326, 530325, 530324, 435233, 506 9, 5303886, 5303873

The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen.

2012009, Apr 19, 2012

Apr 10, 2009

13/262752

Lawrence H. Fong - Palo Alto CA, US
Yafei Hou - Mountain View CA, US
Jason J. Devoss - San Francisco CA, US
Mark Stuart Anderson - Larkspur CA, US

A61K 39/00
C12Q 1/68
G01N 33/567
A61P 35/00
C12N 9/96
A61K 39/395
A61P 13/08
A61P 37/02
G01N 33/53
C07K 14/435

4241391, 436501, 435 612, 435 721, 530350, 435188, 4241851

The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.

2021012, Apr 29, 2021

Dec 31, 2020

17/139311

- Boulder CO, US
Randy Yang Chiang - San Francisco CA, US
Lawrence Herman Fong - San Francisco CA, US

A45F 5/00
A45D 40/18

An expandable device includes a platform having top and bottom sides, a body having a first end and a second end, the second end being operably coupled to the platform, a button operably coupled to the first end of the body, and a storage receptacle defined by at least one of the button, the platform, and the body. The body is movable between an expanded configuration and a collapsed configuration.

2020026, Aug 27, 2020

Sep 24, 2018

16/646512

- Oakland CA, US
Lawrence FONG - Oakland CA, US

A61K 35/17
C12N 5/0783
C12N 15/113
C07K 16/28
A61K 39/395
A61K 45/06
A61P 35/00

T-cells that does not express a functional Interferon-γ (IFN-γ) receptor are provided as well as methods of treating cancers with the T-cells, optionally in combination with immune checkpoint pathway inhibitors.

2020003, Feb 6, 2020

Jul 25, 2019

16/522317

- Boulder CO, US
Randy Yang Chiang - San Francisco CA, US
Lawrence Herman Fong - San Francisco CA, US

A45F 5/00
A45D 40/18

An expandable device includes a platform having top and bottom sides, a body having a first end and a second end, the second end being operably coupled to the platform, a button operably coupled to the first end of the body, and a storage receptacle defined by at least one of the button, the platform, and the body. The body is movable between an expanded configuration and a collapsed configuration.

2019037, Dec 12, 2019

Jan 19, 2018

16/479211

- Oakland CA, US
Lawrence Fong - San Francisco CA, US

G16B 25/10
A61K 38/19
G01N 33/50
A61K 39/395
C07K 16/28
G16B 5/10
G16B 45/00

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127PD-1T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

2018002, Jan 25, 2018

Jul 14, 2017

15/649948

- TAOYUAN CITY, TW
NICHOLE SUZANNE ROUILLAC - SAN FRANCISCO CA, US
KRISTINA NICOLE MARRERO - SAN FRANCISCO CA, US
ROBIN NICHOLAS HUBBARD - SAN FRANCISCO CA, US
MATHIAS ANDREAS HINTERMANN - SAN FRANCISCO CA, US
LAWRENCE HERMAN FONG - SAN FRANCISCO CA, US
MICHAEL CHE HO KEOGAN LO - SAN FRANCISCO CA, US
STUART KYLE - SAN FRANCISCO CA, US
HSIN-HAO LEE - TAOYUAN CITY, TW
HAN-WEN YEH - TAOYUAN CITY, TW

HTC CORPORATION - TAOYUAN CITY

A44C 5/00
A61B 5/024

A wearable device, which comprises a wristband, an electronic module and a connector. The wristband comprises a housing and a band. The housing has a first end, a second end, and an accommodating space. The band has a first end extending from the first end of the housing, and a free second end opposite to the first end of the band. The electronic module disposes within the accommodating space. The connector disposes either at the second end of the housing, or at a first end of the electronic module that is closer to the second end of the housing than the first end of the housing, wherein the free second end of the band is insertable through or into the connector. Wherein there is free of any band between the second end of the housing and the connector and between the first end of the electronic module and the connector.